X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (496) 496
Paper (208) 208
Publication (192) 192
Book / eBook (26) 26
Newspaper Article (21) 21
Patent (7) 7
Book Chapter (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (215) 215
particle physics (210) 210
physics - high energy physics - experiment (205) 205
high energy physics - experiment (152) 152
physics (144) 144
particle physics - experiment (93) 93
high energy physics (84) 84
hep (80) 80
humans (77) 77
ex (74) 74
oncology (70) 70
experimental results (65) 65
cern lhc coll (61) 61
index medicus (58) 58
p p: colliding beams (57) 57
p p: scattering (56) 56
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (46) 46
female (46) 46
male (43) 43
aged (42) 42
7000 gev-cms8000 gev-cms (40) 40
middle aged (40) 40
adult (39) 39
lhc-b (39) 39
physics, particles & fields (39) 39
hadron-hadron scattering (35) 35
hep-ex (35) 35
cancer (33) 33
nuclear experiment (31) 31
neoplasms - drug therapy (29) 29
lhcb (26) 26
phenomenology (26) 26
statistical (26) 26
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (24) 24
colliding beams [p p] (24) 24
b physics (23) 23
care and treatment (23) 23
scattering [p p] (23) 23
aged, 80 and over (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
cp: violation (18) 18
physics, multidisciplinary (18) 18
treatment outcome (18) 18
tumors (18) 18
antineoplastic agents - therapeutic use (17) 17
tool (17) 17
analysis (16) 16
decay (16) 16
metastasis (16) 16
astrophysics (15) 15
clinical trials (15) 15
physics of elementary particles and fields (15) 15
therapy (15) 15
to be checked by faculty (15) 15
chemotherapy (14) 14
cp violation (14) 14
medicine & public health (14) 14
asymmetry: cp (13) 13
flavor physics (13) 13
studies (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
astronomy & astrophysics (12) 12
cell lung-cancer (12) 12
drug administration schedule (12) 12
gemcitabine (12) 12
lhcb - abteilung hofmann (12) 12
muon: pair production (12) 12
neoplasm staging (12) 12
neoplasms - pathology (12) 12
pharmacology & pharmacy (12) 12
protein kinase inhibitors - therapeutic use (12) 12
science & technology (12) 12
cancer therapies (11) 11
dose-response relationship, drug (11) 11
elementary particles, quantum field theory (11) 11
physical sciences (11) 11
quantum field theories, string theory (11) 11
rare decay (11) 11
research (11) 11
antineoplastic agents - adverse effects (10) 10
cisplatin (10) 10
experiments (10) 10
lung neoplasms - drug therapy (10) 10
pharmacology/toxicology (10) 10
solid tumors (10) 10
animals (9) 9
antibodies, monoclonal - therapeutic use (9) 9
antineoplastic agents - administration & dosage (9) 9
bevacizumab (9) 9
bottom mesons (9) 9
branching fraction (9) 9
carcinoma, renal cell - drug therapy (9) 9
collisions (9) 9
d0 anti-d0: mixing (9) 9
drug therapy (9) 9
física de partícules (9) 9
hematology, oncology and palliative medicine (9) 9
historia (9) 9
kidney neoplasms - drug therapy (9) 9
medical research (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 883 - 895
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9704, pp. 1821 - 1830
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7691, pp. 189 - 194
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 4, pp. 350 - 357
Journal Article
Cancer Cell, ISSN 1535-6108, 05/2018, Volume 33, Issue 5, pp. 853 - 861.e4
Journal Article
The Oncologist, ISSN 1083-7159, 03/2019, Volume 24, Issue 3, pp. 338 - 348
Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune... 
Immune checkpoint inhibitors | Renal cell carcinoma | Targeted therapy | Immunotherapy | Tyrosine kinase inhibitors | PROGRESSION-FREE SURVIVAL | BLIND PHASE-III | OPEN-LABEL | ANTITUMOR-ACTIVITY | ANTIANGIOGENIC THERAPY |